Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 456Lymphoid 347Other hematologic neoplasm 159Myeloid 27Genitourinary 19Dermatologic 19Gastrointestinal 15CNS 12Classical hematology 9Sarcoma 8Thoracic 6Gynecologic 6Tumor-Agnostic 5Other solid neoplasm 5Head & Neck 4Endocrine 2Breast 2NET 1

Conditions

Thyroid cancer, Hurthle cell 1Thyroid Cancer, Papillary 1Neuroendocrine Tumors 1Kidney Neoplasms 1Adenocarcinoma, Follicular 1

Interventions

Everolimus 59lutetium Lu 177 dotatate 46Magnetic Resonance Spectroscopy 33pembrolizumab 31Temozolomide 31Cisplatin 29Nivolumab 26Octreotide 24lanreotide 23cabozantinib 22pasireotide 21gallium Ga 68 dotatate 21lenvatinib 20Etoposide 19Specimen Handling 18Paclitaxel 18Carboplatin 18Capecitabine 18Sunitinib 17Bevacizumab 16trametinib 15dabrafenib 15Doxorubicin 143-Iodobenzylguanidine 14surufatinib 13Sorafenib 13Ipilimumab 13Thyrotropin Alfa 12Injections 12Positron Emission Tomography Computed Tomography 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Lenalidomide × Endocrine × Clear all
NCT01218555 2022-01-27

Study of Everolimus (RAD001) in Combination With Lenalidomide

Emory University

Phase 1 Completed
44 enrolled 9 charts
EndocrineGenitourinaryNET

Kidney Neoplasms, Neuroendocrine Tumors

NCT01208051 2021-07-15

Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
127 enrolled 18 charts
EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid Cancer, Papillary, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡